Mutations in the UNC93B1 gene — which produces a protein involved in the regulation of certain immune proteins, called toll-like receptors, or TLRs — may drive autoimmunity in people with lupus and other autoimmune conditions, according to a new study into the genetic cause of lupus and related diseases.
Discontinuing glucocorticoid therapy after achieving remission did not increase the risk of symptom flare-ups in people with systemic lupus erythematosus (SLE). That’s according to data presented at the 2024 European Alliance of Associations for Rheumatology (EULAR) congress, as announced in a EULAR press release. Data also showed that…
The six recipients of Lupus Foundation of America (LFA)’s 2024 fellowships for young scientists will use their awards to study several areas of lupus, ranging from lupus nephritis to the connection between physical activity and physical function in people with the autoimmune disease. The goal of the 40-year-old…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to CAR T-cell therapy ADI-001 as a potential treatment for lupus nephritis, a lupus complication marked by kidney damage and inflammation. The FDA gives fast track status to experimental treatments that have the potential to fill unmet…
GRI Bio announced what it called “encouraging preclinical data” on two systemic lupus erythematosus (SLE) treatment candidates. SLE is the most common form of lupus. GRI-0124, an oral small molecule being developed to activate natural killer T-cells, or NKT cells, and keep autoimmune attacks in check eased inflammation…
A dual-target CAR T-cell therapy from iCell Gene Therapeutics safely led to medication-free disease remission for systemic lupus erythematosus (SLE) patients in a small Phase 1 study. For patients with lupus nephritis (LN), a common and serious SLE manifestation involving the kidneys, renal function also was improved. Based…
The U.S. Food and Drug Administration (FDA) has approved the use of Benlysta (belimumab) in a prefilled autoinjector as an add-on treatment for children ages 5 and older with systemic lupus erythematosus (SLE), the most common form of lupus. This is the first time children with active disease…
Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms and severity of systemic lupus erythematosus (SLE), a study shows. While IFNs are known to play a role in the disease, increases in IFN levels don ‘t explain many…
A 27-year-old woman with hard-to-treat systemic lupus erythematosus (SLE), the most common type of lupus, became the first patient treated in an early clinical trial evaluating FT819, Fate Therapeutics’ off-the-shelf CAR T-cell therapy candidate. The Phase 1 study (NCT06308978), taking place at the University of Minnesota Medical…
Inflammatory macrophages, a type of immune cell tasked with clearing the body of harmful invaders and dead cells, may be linked to more severe lupus nephritis in children with systemic lupus erythematosus, a small study suggests. Those immune cells, called M1-like macrophages, appear to play a more important role…